Showing results (81-90 of 369) with videos related to
Sort By:
Pageof 37
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis ImagingNeeta Pandit-Taskar, Darren R Veach, Josef J Fox, et al.JCO Oncology Practice|February 17, 2022
Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant EtiologiesLisa Marie Ruppert, Erica Dayan Cohn, Niamh M Keegan, et al.The Journal of Urology|February 21, 2017
Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical ProstatectomyNicola L Robertson, Evis Sala, Matthias Benz, et al.Urology|July 13, 2004
Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancerCharles J Ryan, Michael J Zelefsky, Glenn Heller, et al.Radiology|April 6, 2004
Suspected local recurrence after radical prostatectomy: endorectal coil MR imagingTamar Sella, Lawrence H Schwartz, Peter W Swindle, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2002
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancerWilliam D Fox, Brian Higgins, Krista M Maiese, et al.Cancer Research|December 18, 2003
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroidsRichard Enmon, Wei-Hong Yang, Ase M Ballangrud, et al.Proceedings of the National Academy of Sciences of the United States of America|August 22, 2002
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxinLisa M Butler, Xianbo Zhou, Wei-Sheng Xu, et al.Clinical Prostate Cancer|October 4, 2005
Second-line chemotherapy for prostate cancer: patient characteristics and survivalKathleen W Beekman, Mark T Fleming, Howard I Scher, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2021
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort StudyAndreas G Wibmer, Michael J Morris, Mithat Gonen, et al.Pageof 37